Current concepts review: A review of osteocyte function and the emerging importance of sclerostin

Journal of Bone and Joint Surgery - American Volume

Volumn 96, Issue 19, 2014, Pages 1659-1668

  Compton, Jocelyn T ^a   Lee, Francis Y ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PARATHYROID HORMONE; PROSTAGLANDIN E2; PROTEIN ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

BIOMECHANICS; BONE CANCER; BONE DENSITY; BONE IMPLANT; BONE MASS; BONE METABOLISM; BONE METASTASIS; CELL FUNCTION; CELL POPULATION; CELL SURFACE; DEVICE FAILURE; FRACTURE HEALING; FRAGILITY FRACTURE; GENETIC DISORDER; HUMAN; NERVE CELL NETWORK; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTEMIC CIRCULATION; BONE DISEASE; BONE TUMOR; GENETIC MARKER; GENETICS; METASTASIS; MOLECULARLY TARGETED THERAPY; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTHESES AND ORTHOSES;

BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; FRACTURE HEALING; GENETIC MARKERS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOCYTES; OSTEOPOROSIS; PROSTHESES AND IMPLANTS;

EID: 84907483743     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.M.01096     Document Type: Review

References (128)

1. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011 Oct;17(10):1231-4. Epub 2011 Sep 11.
2. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008 May 15;473(2):231-6. Epub 2008 Mar 23.
3. Weinstein LS, Xie T, Zhang QH, Chen M. Studies of the regulation and function of the Gs alpha gene Gnas using gene targeting technology. Pharmacol Ther. 2007 Aug;115(2):271-91. Epub 2007 Apr 21.
4. Kwon R, Meays D, Kardos N, Frangos J. Regulation of energy metabolism by osteocytes. J Bone Miner Res. 2010; 25(Suppl 1).
5. Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete JM, Fruhbeck G, Martinez C, Idoate F, Salvador J, Forga L, Ricart W, Ibanez J. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab. 2009 Jan;94(1):237-45. Epub 2008 Oct 14.
6. Clemens TL, Karsenty G. The osteoblast: An insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011 Apr;26(4):677-80.
7. Breuil V, Euller-Ziegler L. Gonadal dysgenesis and bone metabolism. Joint Bone Spine. 2001 Feb;68(1):26-33.
8. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW. The osteocyte. Int J Biochem Cell Biol. 2004 Jan;36(1):1-8.
9. Buckwalter JA, Cooper RR. Bone Biology. J Bone Joint Surg Am. 1995 Aug 1;77(8):1276-1289.
10. Palumbo C, Palazzini S, Marotti G. Morphological study of intercellular junctions during osteocyte differentiation. Bone. 1990;11(6):401-6.
11. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: An endocrine cell ... and more [Epub ahead of print]. Endocr Rev. 2013 Oct;34(5):658-90. Epub 2013 Apr 23.
12. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011 Feb;26(2):229-38.
13. Holtrop ME. Light and electron microscopical structure of bone forming cells. In: Hall BK, editor. Bone: A treatise, Vol 1: The osteoblast and osteocyte. Caldwell, NJ: The Telford Press; 1990. p 1-40.
14. Palumbo C. A three-dimensional ultrastructural study of osteoid-osteocytes in the tibia of chick embryos. Cell Tissue Res. 1986;246(1):125-31.
15. Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001 Feb;28(2):145-9.
16. Palumbo C, Palazzini S, Zaffe D, Marotti G. Osteocyte differentiation in the tibia of newborn rabbit: An ultrastructural study of the formation of cytoplasmic processes. Acta Anat (Basel). 1990;137(4):350-8.
17. Aarden EM, Burger EH, Nijweide PJ. Function of osteocytes in bone. J Cell Biochem. 1994 Jul;55(3):287-99.
18. Ramp WK. Cellular control of calcium movements in bone. Interrelationships of the bone membrane, parathyroid hormone and alkaline phosphatase. Clin Orthop Relat Res. 1975 Jan-Feb;(106):311-22.
19. Knothe Tate ML, Niederer P, Knothe U. In vivo tracer transport through the lacunocanalicular system of rat bone in an environment devoid of mechanical loading. Bone. 1998 Feb;22(2):107-17.
20. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: how osteoblasts become osteocytes. Dev Dyn. 2006 Jan;235(1):176-90.
21. Dallas SL, Bonewald LF. Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci. 2010 Mar;1192(1):437-43.
22. Zhao W, Byrne MH, Wang Y, Krane SM. Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest. 2000 Oct;106(8):941-9.
23. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci. 2005 Jan 1;118(Pt 1):147-56. Epub 2004 Dec 15.
24. van der Plas, A, Aarden, EM, Feijen, JH, de Boer, AH, Wiltink, A, Alblas, MJ, de Leij, L, Nijweide, PJ. Characteristics and properties of osteocytes in culture. J Bone Miner Res. 1994 Nov;9(11):1697-704.
25. Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers- Schonberg's disease. J Bone Joint Surg Br. 1958 May;40(2):209-18.
26. Balemans W, EbelingM, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001 Mar 1;10(5):537-43.
27. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001 Mar;68(3):577-89. Epub 2001 Feb 9.
28. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008 Jun;23(6):860-9.
29. Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis. 2011 Mar;70 Suppl 1:119-22.
30. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010 Aug;87(2):99-107.
31. Okazaki R. [Anti-sclerostin antibodies]. Clin Calcium. 2011 Jan;21(1):94-8. [Article in Japanese].
32. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009 Apr;24(4):578-88.
33. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res. 2011 Jul;26(7):1425-36.
34. Marotti G, Farneti D, Remaggi F, Tartari F. Morphometric investigation on osteocytes in human auditory ossicles. Ann Anat. 1998 Oct;180(5):449-53.
35. Nicolella DP, Moravits DE, Gale AM, Bonewald LF, Lankford J. Osteocyte lacunae tissue strain in cortical bone. J Biomech. 2006;39(9):1735-43. Epub 2005 Jul 1.
36. Bonivtch AR, Bonewald LF, Nicolella DP. Tissue strain amplification at the osteocyte lacuna: A microstructural finite element analysis. J Biomech. 2007;40(102199-206):. Epub 2007 Jan 2.
37. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003 Dec 1;22(23):6267-76.
38. Robling AG, Bellido T, Turner CH. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact. 2006 Oct- Dec;6(4):354.
39. Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012 Sep;97(9):1736-40. Epub 2012 Jul 5.
40. Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, Garshick E, Battaglino RA. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012 Feb;27(2):352-9.
41. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/betacatenin signaling. J Bone Miner Res. 2009 Oct;24(10):1651-61.
42. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/betacatenin signaling. J Bone Miner Res. 2009 Oct;24(10):1651-61.
43. Ott SM. Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab. 2005 Dec;90(12):6741-3.
44. Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML, Robling AG. High-bonemass- producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes. Bone. 2011 Nov;49(5):1010-9. Epub 2011 Aug 9.
45. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005 May 20;280(20):19883-7. Epub 2005 Mar 18.
46. Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther. 2013 Feb;13(2):183-96. Epub 2012 Dec 19.
47. Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimbimmobilization rat model. Bone. 2011 Feb;48(2):197-201. Epub 2010 Sep 17.
48. Genetos DC, Yellowley CE, Loots GG. Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression. PLoS One. 2011;6(3):e17772. Epub 2011 Mar 16.
49. Genetos DC, Toupadakis CA, Raheja LF, Wong A, Papanicolaou SE, Fyhrie DP, Loots GG, Yellowley CE. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010 May 15;110(2):457-67.
50. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, ConstableMJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010 Feb;120(2):582-92. Epub 2010 Jan 4.
51. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008 Dec;23(12):2025-32.
52. Cornish J, Callon K, King A, Edgar S, Reid IR. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology. 1993 Mar;132(3):1359-66.
53. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res. 2009 Aug;24(8):1434-49.
54. Schipani E, Kruse K, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science. 1995 Apr 7;268(5207):98-100.
55. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001 Feb;107(3):277-86.
56. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, StolinaM, Kostenuik P, Khosla S. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62. Epub 2010 Jul 14.
57. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003 Dec 12;278(50):50259-72. Epub 2003 Oct 1.
58. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005 Nov;146(11):4577-83. Epub 2005 Aug 4.
59. Zaman G, Jessop HL, Muzylak M, De Souza RL, Pitsillides AA, Price JS, Lanyon LL. Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. J Bone Miner Res. 2006 Aug;21(8):1297-306.
60. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997 Sep;82(9):3128-35.
61. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011 Jan;26(1):27-34.
62. Lapauw B, Vandewalle S, Taes Y, Goemaere S, Zmierczak H, Collette J, Kaufman JM. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013 Apr;168(4):615-20. Epub 2013 Mar 15.
63. Jahn K, Lara-Castillo N, Brotto L, Mo CL, Johnson ML, Brotto M, Bonewald LF. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of b-catenin. Eur Cell Mater. 2012;24:197-209; discussion 209-10. Epub 2012 Sep 12.
64. Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, Leone CW, Morgan EF, Gerstenfeld LC, Einhorn TA, Graves DT. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007 Apr;22(4):560-8.
65. Kayal RA, Alblowi J, McKenzie E, Krothapalli N, Silkman L, Gerstenfeld L, Einhorn TA, Graves DT. Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone. 2009 Feb;44(2): 357-63. Epub 2008 Oct 29.
66. Hirakawa K, Hirota S, Ikeda T, Yamaguchi A, Takemura T, Nagoshi J, Yoshiki S, Suda T, Kitamura Y, Nomura S. Localization of the mRNA for bone matrix proteins during fracture healing as determined by in situ hybridization. J Bone Miner Res. 1994 Oct;9(10):1551-7.
67. Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alias AM, Lowik C, Papapoulos S, Reeve J, Loveridge N. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res. 2010 Aug;25(8):1867-76.
68. Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: The cellular picture. Semin Cell Dev Biol. 2008 Oct;19(5):459-66. Epub 2008 Jul 25.
69. Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ, Lee E, Liu M, Simonet WS, Paszty C, Ke HZ. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone. 2011 Dec;49(6):1178- 85. Epub 2011 Aug 26.
70. Cui L, Cheng H, Song C, Li C, Simonet WS, Ke HZ, Li G. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact. 2013 Jun;13(2):178-84.
71. Virk MS, Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am. 2013 Apr 17;95(8):694-701.
72. Jawad MU, Fritton KE, Ma T, Ren PG, Goodman SB, Ke HZ, Babij P, Genovese MC. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res. 2013 Jan;31(1):155-63. Epub 2012 Aug 8.
73. Taut AD, Jin Q, Chung JH, Galindo-Moreno P, Yi ES, Sugai JV, Ke HZ, Liu M, Giannobile WV. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013 Nov;28(11):2347-56.
74. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S. Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res. 2012 Oct;30(10):1549-55. Epub 2012 Apr 16.
75. Secreto FJ, Hoeppner LH, Westendorf JJ. Wnt signaling during fracture repair. Curr Osteoporos Rep. 2009 Jul;7(2):64-9.
76. Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: A randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013 Aug;98(8):3206-12. Epub 2013 Jun 20.
77. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The Center of Excellence for Osteoporosis Research Study. J Bone Miner Res. 2012 Dec;27(12):2592-602.
78. Caetano-Lopes J, Lopes A, Rodrigues A, Fernandes D, Perpetuo IP, Monjardino T, Lucas R, Monteiro J, Konttinen YT, Canhao H, Fonseca JE. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. PLoS One. 2011;6(2):e16947. Epub 2011 Feb 11.
79. McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res. 2012 Oct;30(10):1541-8. Epub 2012 Mar 27.
80. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011 May;26(5):1012-21.
81. Grandjean-Laquerriere A, Laquerriere P, Guenounou M, Laurent-Maquin D, Phillips TM. Importance of the surface area ratio on cytokines production by human monocytes in vitro induced by various hydroxyapatite particles. Biomaterials. 2005 May;26(15):2361-9.
82. Lange T, Schilling AF, Peters F, Haag F, Morlock MM, Rueger JM, Amling M. Proinflammatory and osteoclastogenic effects of beta-tricalciumphosphate and hydroxyapatite particles on human mononuclear cells in vitro. Biomaterials. 2009 Oct;30(29):5312-8. Epub 2009 Jul 3.
83. Zhang Y, Yan M, Yu A, Mao H, Zhang J. Inhibitory effects of b-tricalciumphosphate wear particles on osteocytes via apoptotic response and Akt inactivation. Toxicology. 2012 Jul 16;297(1-3):57-67. Epub 2012 Apr 12.
84. Liu S, Virdi AS, Sena K, Sumner DR. Sclerostin antibody prevents particleinduced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model. Arthritis Rheum. 2012 Dec;64(12):4012-20.
85. Virdi AS, Liu M, Sena K, Maletich J, McNulty M, Ke HZ, Sumner DR. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am. 2012 Sep 19;94(18):1670-80.
86. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5.
87. Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E. Sclerostin: A possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets. 2012 Aug;16(8):761-9. Epub 2012 Jul 5.
88. Coluzzi F, Di Bussolo E, Mandatori I, Mattia C. Bone metastatic disease: Taking aim at new therapeutic targets. Curr Med Chem. 2011;18(20):3093-115.
89. Coluzzi F, Mandatori I, Mattia C. Emerging therapies in metastatic bone pain. Expert Opin Emerg Drugs. 2011 Sep;16(3):441-58. Epub 2011 May 5.
90. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003 Mar 15;101(6):2094-8. Epub 2002 Nov 7.
91. Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G, Rinaldi E, Curci P, Liso V, Passeri G, Zallone A, Rizzi R, Grano M. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011 Jun;1(6):27. Epub 2011 Jun 24.
92. Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction postbortezomib monotherapy. Int J Cancer. 2012 Sep 15;131(6):1466-71. Epub 2011 Dec 21.
93. Masrour Roudsari J, Mahjoub S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget's specimens. Caspian J Intern Med. 2012 Summer;3(3):478-83.
94. Pabinger C, Heu C, Frohner A, Dimai HP. Pregnancy- and lactation-associated transient osteoporosis of both hips in a 32 year old patient with osteogenesis imperfecta. Bone. 2012 Jul;51(1):142-4.
95. Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis. 2014 Feb;31(2):247-56.
96. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005 Sep 15;65(18):8274-85.
97. Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012 Jul;51(1):153-7. Epub 2012 May 2.
98. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):25900. Epub 2011 Oct 4.
99. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem. 2003 Dec 5;278(49):48684-9. Epub 2003 Sep 23.
100. Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFb-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res. 2011;13(5):R106. Epub 2011 Oct 27.
101. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat. 2011 Oct;129(3):737-46. Epub 2010 Nov 27.
102. Bhadada SK, Rastogi A, Steenackers E, Boudin E, Arya A, Dhiman V, Bhansali A, Van Hul W. Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone. 2013 Feb;52(2):707-10. Epub 2012 Oct 16.
103. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005 Jun;36(6):943-7.
104. Kim CA, Honjo R, Bertola D, Albano L, Oliveira L, Jales S, Siqueira J, Castilho A, Balemans W, Piters E, Jennes K, Van Hul W. A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin. Genet Test. 2008 Dec;12(4):475-9.
105. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002 Feb;39(2):91-7.
106. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002 Jun 15;110(2):144-52.
107. van Bezooijen, RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals, L, Balemans W, Oostenbroek HJ, Van Hul, W, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009 Jun;88(6):569-74.
108. van Lierop, AH, Hamdy NA, van Egmond, ME, Bakker E, Dikkers FG, Papapoulos SE. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013 Apr;28(4):848-54.
109. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/1 mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013 Jan;28(1):73-80.
110. Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012;13:191. Epub 2012 Oct 2.
111. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res. 2012 Nov;44(12):909-13. Epub 2012 May 11.
112. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN, Little CB. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage. 2011 Jul;19(7):874-85. Epub 2011 May 12.
113. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009 Nov;24(11):1879-88.
114. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010 Sep;47(3):529-33. Epub 2010 Jun 1.
115. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010 Dec;25(12):2647-56. Epub 2010 Jul 16.
116. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011 Jan;26(1):19-26.
117. Reid IR. Osteoporosis treatment (ECTS 2013). In: IBMS BoneKEy. Meeting Report from the European Calcified Tiessue Society Annual Congress; Lisbon, Portugal; 2013 May 18-21. Article no. 392.
118. Amgen MD. Study to assess fracture healing with sclerostin antibody. U.S. National Institutes of Health. 2000. http://clinicaltrials.gov/ct2/show/NCT01081678. Accessed 2013 Nov 18.
119. Cain CJ, Rueda R, McLelland B, Collette NM, Loots GG, Manilay JO. Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res. 2012 Jul;27(7):1451-61.
120. Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012 Jun;26(6):1391-401. Epub 2012 Jan 6.
121. Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, Stokkers PC, Oldenburg B, Netelenbos JC, Hommes DW, van Bodegraven AA, Lips P; Dutch Initiative on Crohn and Colitis (ICC). Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease. Gastroenterology. 2011 Jan;140(1):116-23. Epub 2010 Sep 18.
122. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009 Oct;24(10):1662-71.
123. Bonewald LF. Osteocytes. In: Marcus R, Feldman D, Nelson DA, Rosen CJ, editors. Osteoporosis. 3rd ed. Vol 1. Elsevier; 2007. p 169-90.
124. Bonewald LF. Osteocyte biology: its implications for osteoporosis. J Musculoskelet Neuronal Interact. 2004 Mar;4(1):101-4.
125. Carpentier VT, Wong J, Yeap Y, Gan C, Sutton-Smith P, Badiei A, Fazzalari NL, Kuliwaba JS. Increased proportion of hypermineralized osteocyte lacunae in osteoporotic and osteoarthritic human trabecular bone: implications for bone remodeling. Bone. 2012 Mar;50(3):688-94. Epub 2011 Dec 7.
126. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010 Jun;151(6):2641-9. Epub 2010 Apr 21.
127. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61.
128. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized doubleblind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002 Oct;87(10):4528-35.